Table 2 Overview of studies with everolimus
From: Practical considerations for the use of mTOR inhibitors
Author | Study arm | Control arm | Outcome |
|---|---|---|---|
Bas + CsA + MPS + S early conversion to EVR | Bas + CsA + MPS + S | Better GFR EVR arm at 1 yr and at 5 yrs (72 vs. 62 mL/min at 1 yr); overall higher rate of AR | |
Mjörnstedt et al. [16] | CsA + MPS + S early conversion to EVR (7 weeks) | CsA + MPS + S | GFR change 4.9 vs 0 mL/min (EVR vs CsA) |
Langer et al. [17] | Bas + Tac low + EVR + S + conversion Tac very low | Bas + Tac low + EVR + S | No difference in AR post-conversion; GFR 57 vs. 51 mL/min (p = 0.0299) |